Orang'o Elkanah, Itsura Peter, Tonui Philip, Muliro Hellen, Rosen Barry, van Lonkhuijzen Luc
, , , and , Moi University School of Medicine, Eldoret, Kenya; , Oakland University, Rochester, MI; , Academic Medical Center, Amsterdam, the Netherlands.
J Glob Oncol. 2016 Nov 2;3(5):539-544. doi: 10.1200/JGO.2016.006411. eCollection 2017 Oct.
To evaluate the effectiveness and feasibility of cisplatinum for palliative treatment of advanced cervical cancer in a resource-poor setting.
An observational case series is reported from a university teaching hospital in Kenya. All women presenting with advanced cervical cancer and planned for palliative cisplatinum therapy from 2010 to 2014 were included. Women were treated with cisplatinum 50 mg/m every 4 weeks in an outpatient setting. Data on tumor stage and symptoms control were prospectively collected in an electronic database. The main outcome measure was control of symptoms such as bleeding, discharge, and pain.
Of the women who originally presented with bleeding, 62% reported improvement in this symptom, 31.3% reported the bleeding completely stopped, 58% had improvement of their vaginal discharge, and 20.5% reported complete resolution. Of the women who presented with pain, 54% reported improvement; 30.9% reported pain had completely resolved. After each treatment cycle, approximately 30% of patients did not return for their next treatment.
Cisplatinum as palliative treatment of advanced cervical cancer is feasible in a resource-poor setting and leads to effective symptom control. However, unknown barriers may inhibit women from returning for regular treatment.
评估顺铂在资源匮乏地区用于晚期宫颈癌姑息治疗的有效性和可行性。
报告了肯尼亚一所大学教学医院的一个观察性病例系列。纳入了2010年至2014年所有被诊断为晚期宫颈癌并计划接受顺铂姑息治疗的女性。这些女性在门诊每4周接受50mg/m的顺铂治疗。肿瘤分期和症状控制的数据前瞻性地收集于一个电子数据库中。主要结局指标是对出血、排液和疼痛等症状的控制。
最初有出血症状的女性中,62%报告该症状有所改善,31.3%报告出血完全停止,58%的阴道排液有所改善,20.5%报告排液完全消失。有疼痛症状的女性中,54%报告疼痛有所改善;30.9%报告疼痛完全缓解。每个治疗周期后,约30%的患者未返回接受下一周期治疗。
顺铂作为晚期宫颈癌的姑息治疗在资源匮乏地区是可行的,并能有效控制症状。然而,未知的障碍可能会阻碍女性返回接受常规治疗。